Skip to content

CYTO

Altamira Therapeutics Ltd.

NASDAQ · Healthcare · Biotechnology · BM

$0.30
+0.00%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-100.0%
EBITDA
+92.3%
EBIT
+67.2%
Net income
+72.6%
EPS
+97.5%
Free cash flow
-6.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2023